Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/visen-announces-acceptance-of-a-biologics-license-application-for-lonapegsomatropin-in-china-302082740.html
https://www.prnewswire.com/news-releases/double-blind-period-completes-primary-endpoint-analysis-of-phase-3-clinical-trial-to-be-conducted-for-chinas-first-hormone-replacement-treatment-targeting-hypoparathyroidism-301715285.html
https://www.prnewswire.com/news-releases/visen-discloses-52-week-clinical-results-for-its-china-phase-3-trial-of-lonapegsomatropin-301681121.html
https://www.globenewswire.com/news-release/2022/05/23/2448375/0/en/Positive-Results-from-VISEN-s-Phase-3-Trial-of-Once-Weekly-TransCon-hGH-in-China-Consistent-with-Ascendis-Pharma-s-Phase-3-Height-Trial.html
https://www.prnewswire.com/news-releases/visen-pharmaceuticals-announces-top-line-results-of-phase-3-trial-of-once-weekly-lonapegsomatropin-demonstrating-superior-efficacy-comparable-safety-and-tolerability-to-daily-growth-hormone-301552704.html
https://www.prnewswire.com/news-releases/the-first-hormone-replacement-therapy-for-hypoparathyroidism-in-china-obtains-ind-approval-for-phase-iii-clinical-trial-301305526.html